{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:04:55Z","timestamp":1782846295859,"version":"3.54.5"},"reference-count":32,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Adjuvant endocrine therapy is a cornerstone in managing estrogen receptor\u2013positive early breast cancer but may adversely affect metabolic health, including weight gain, insulin resistance, and dyslipidemia. These changes increase the risk of cardiovascular disease and may influence breast cancer outcomes. However, the timing and magnitude of early metabolic changes following endocrine therapy initiation remain poorly characterized. Conventional definitions such as metabolic syndrome rely on dichotomous thresholds and may lack sensitivity to detect early treatment-related metabolic changes, highlighting the need for refined assessment approaches.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This prospective follow-up study aims to investigate early metabolic effects of initiating adjuvant endocrine therapy in women with estrogen receptor\u2013positive early breast cancer and to compare conventional and expanded approaches to metabolic health classification.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This single-center, prospective observational study was conducted at Aarhus University Hospital, Denmark. Women aged\u226518 years with early-stage estrogen receptor\u2013positive breast cancer initiating adjuvant endocrine therapy and without pre-existing diabetes were eligible. Metabolic health was assessed at baseline and after 3 months using biometric measurements (weight, waist and hip circumference, waist-to-hip ratio, and blood pressure) and non-fasting blood samples (plasma glucose; hemoglobin A\n 1c,<\/jats:sub>\n (HbA\n 1c<\/jats:sub>\n ); lipid profile; and estradiol). The 3-month follow-up was selected to capture early metabolic changes while aligning with routine clinical care to minimize additional visits and reduce selection bias. Metabolic health will be evaluated using two conventional measures and two extended, exploratory measures. Conventional measures are metabolic syndrome (MetS), defined as meeting \u22653 of 5 established criteria (blood pressure \u2265130\/85 mmHg, triglycerides >2 mmol\/l, high-density lipoprotein cholesterol <1.295 mmol\/l, waist circumference >88 cm, and plasma glucose >7.8 mmol\/l), and the Metabolic Syndrome z score (MetS-Z), a continuous standardized composite of the MetS components. Additional extended measures are exploratory: the extended MetS, which expands the standard MetS definition by incorporating low-density lipoprotein cholesterol (>3 mmol\/l), body mass index (\u226530 kg\/m\u00b2), waist-to-hip ratio (>0.85), and HbA\n 1c<\/jats:sub>\n (\u226542 mmol\/mol), and the EMETA score, a standardized composite of the extended MetS components calculated using the same approach as the MetS-\n z<\/jats:italic>\n score.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study was funded in July 2024. Recruitment occurred between November 2024 and April 2025, and follow-up was completed in September 2025. Statistical analyses are planned for February 2026, with results expected to be published in summer 2026.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study is expected to provide insights into early metabolic changes following initiation of adjuvant endocrine therapy and evaluate different approaches to classifying metabolic health. The aim to inform future research by helping to identify patients at increased risk of cardiometabolic complications and adverse breast cancer outcomes, warranting confirmation and validation of expanded metabolic measures in longer-term, larger cohorts.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/78589","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:05:08Z","timestamp":1769612708000},"page":"e78589-e78589","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Impact of Initiating Endocrine Therapy on Metabolic Health in Early Breast Cancer: Protocol for the Prospective Follow-Up EMETA-Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5276-7195","authenticated-orcid":false,"given":"L\u00e6rke","family":"Nissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6004-0104","authenticated-orcid":false,"given":"Jonas","family":"Busk Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7938-8893","authenticated-orcid":false,"given":"Signe","family":"Borgquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"5","key":"R1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"R2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"R3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030154","article-title":"Perioperative drug management of systemic therapies in breast cancer: a literature review and treatment recommendations","volume":"32","author":"Galuia","journal-title":"Curr Oncol"},{"issue":"7","key":"R4","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","journal-title":"Lancet Oncol"},{"issue":"1","key":"R5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41574-023-00899-0","article-title":"Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy","volume":"20","author":"Thomas","journal-title":"Nat Rev Endocrinol"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00864","article-title":"Breast cancer survivorship, quality of life, and late toxicities","volume":"10","author":"Nardin","journal-title":"Front Oncol"},{"issue":"1","key":"R7","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-024-02002-6","article-title":"Lipid changes during endocrine therapy in early-stage breast cancer patients: a real-world study","volume":"23","author":"Li","journal-title":"Lipids Health Dis"},{"issue":"3","key":"R8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00125-019-05040-3","article-title":"Sex differences in metabolic regulation and diabetes susceptibility","volume":"63","author":"Tramunt","journal-title":"Diabetologia"},{"issue":"4","key":"R9","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15040242","article-title":"Metabolic changes in patients with premature ovarian insufficiency: adipose tissue focus-a narrative review","volume":"15","author":"S\u00e1nchez-Garc\u00eda","journal-title":"Metabolites"},{"issue":"15","key":"R10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.21.01738","article-title":"Risk of cardiometabolic risk factors in women with and without a history of breast cancer: The Pathways Heart Study","volume":"40","author":"Kwan","journal-title":"J Clin Oncol"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-023-06997-x","article-title":"Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer","volume":"201","author":"Rillamas-Sun","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"R12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092254","article-title":"Adjuvant hormonotherapy and cardiovascular risk in post-menopausal women with breast cancer: a large population-based cohort study","volume":"13","author":"Franchi","journal-title":"Cancers (Basel)"},{"issue":"8","key":"R13","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","journal-title":"Circulation"},{"issue":"1","key":"R14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular disease mortality among breast cancer survivors","volume":"27","author":"Bradshaw","journal-title":"Epidemiology"},{"issue":"10","key":"R15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.37780","article-title":"Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors","volume":"6","author":"Harborg","journal-title":"JAMA Netw Open"},{"issue":"12","key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv275","article-title":"Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis","volume":"107","author":"Playdon","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"R17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000496548","article-title":"Body mass index at diagnosis as a prognostic factor for early-stage invasive breast cancer after surgical resection","volume":"42","author":"Wang","journal-title":"Oncol Res Treat"},{"issue":"3","key":"R18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/joim.20052","article-title":"Metabolic syndrome is associated with breast cancer mortality: a systematic review and meta-analysis","volume":"297","author":"Harborg","journal-title":"J Intern Med"},{"issue":"1","key":"R19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-024-00563-5","article-title":"Metabolic syndrome","volume":"10","author":"Neeland","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"R20","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.2337\/dc18-1079","article-title":"Use of a Metabolic syndrome severity score to track risk during treatment of prediabetes: an analysis of the Diabetes Prevention Program","volume":"41","author":"DeBoer","journal-title":"Diabetes Care"},{"issue":"12","key":"R21","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.amjcard.2007.07.027","article-title":"Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise)","volume":"100","author":"Johnson","journal-title":"Am J Cardiol"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S283177","article-title":"Changes in menopausal risk factors in early postmenopausal osteopenic women after 13 months of high-intensity exercise: the randomized controlled ACTLIFE-RCT","volume":"16","author":"Hettchen","journal-title":"Clin Interv Aging"},{"issue":"2","key":"R23","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13780","article-title":"Long-term effects of high-intensity aerobic training on metabolic syndrome: an 8-year follow-up randomized clinical trial","volume":"16","author":"Morales-Palomo","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"R24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/sms.14280","article-title":"High-intensity interval training improves metabolic syndrome in women with breast cancer receiving Anthracyclines","volume":"33","author":"Gonzalo-Encabo","journal-title":"Scand J Med Sci Sports"},{"issue":"17","key":"R25","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","journal-title":"Circulation"},{"issue":"1","key":"R26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-021-01413-4","article-title":"Association of glycated hemoglobin A levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium","volume":"20","author":"Sinning","journal-title":"Cardiovasc Diabetol"},{"key":"R27","unstructured":"EMETA study design and participation. BioRender. URL: https:\/\/BioRender.com\/d5aglhl [Accessed 13-03-2026]"},{"key":"R28","unstructured":"Attribution 4.0 international (CC BY 4.0). Creative Commons. URL: https:\/\/creativecommons.org\/licenses\/by\/4.0\/ [Accessed 13-03-2026]"},{"issue":"9","key":"R29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1200\/JCO.2017.75.7526","article-title":"Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized controlled trial","volume":"36","author":"Dieli-Conwright","journal-title":"J Clin Oncol"},{"issue":"6","key":"R30","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.3390\/curroncol29060326","article-title":"Weight gain after hormone receptor-positive breast cancer","volume":"29","author":"Goyal","journal-title":"Curr Oncol"},{"issue":"1","key":"R31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejca.2008.09.003","article-title":"The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors","volume":"45","author":"Heideman","journal-title":"Eur J Cancer"},{"issue":"2","key":"R32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10549-022-06794-y","article-title":"Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER\u2009+\u2009breast cancer","volume":"197","author":"Bergman","journal-title":"Breast Cancer Res Treat"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e78589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:11:16Z","timestamp":1782843076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e78589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2196\/78589","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"article-number":"v15i5e78589"}}